AbbVie eyes 2nd Rinvoq nod as it hits its marks in psoriatic arthritis

AbbVie eyes 2nd Rinvoq nod as it hits its marks in psoriatic arthritis

Source: 
Fierce Pharma
snippet: 

AbbVie blockbuster-to-be Rinvoq only just hit the scene in rheumatoid arthritis, but it’s already on its way to a second indication.

Thursday, the Illinois drugmaker said its newcomer had hit its primary endpoint in a phase 3 psoriatic arthritis (PsA) trial, topping placebo at reducing symptoms.